Invictus Health Group is closely monitoring all coronavirus (COVID-19) updates and is following best practices from the CDC to prevent the spread of the virus.
September 19, 2019
Digital technology and virtual reality changing the face of mental health treatment
The advancement of digital technology is a boon for multiple sectors. One particular sector that has benefited and can make the most of this technology is the healthcare sector, especially the mental healthcare domain. Digital technology has a lot of potential and can help in mental health treatment. From virtual counseling to treatment across various…Read more
July 26, 2019
Are postpartum anxiety and postpartum depression different?
Motherhood is an exhilarating experience that brings with it a great set of responsibilities and changes. It is considered one of the most gratifying experiences of life, however, for some women, the postpartum stage is challenging as it is darkened by mental health disorders, like anxiety or depression. While a little anxiety is common and…Read more
July 24, 2019
Antidepressants cause withdrawal; Psychiatrists sound warning bells
Patients coming off antidepressants too quickly are suffering from withdrawal symptoms, suggested a recent study by the Royal College of Psychiatrists. The researchers said that patients who have been taking antidepressants for a long time are experiencing serious side effects which require immediate support and help. Antidepressants are medications prescribed by mental health practitioners to…Read more
June 18, 2019
International Father’s Mental Health Day – The need to celebrate fathers
Post-partum depression in new fathers common Nearly 6 million men struggle with depression every year, according to the Mental Health America (MHA). However, in majority of the cases, this depression remains undiagnosed and thus untreated. In comparison to women, who feel worthless and sad when depressed, men tend to get fatigued, irritable, aggressive, or lose…Read more
June 13, 2019
FDA approves Spravato – ketamine related drug for treatment-resistant depression
The Food and Drug Administration (FDA) has recently approved Spravato, a nasal spray manufactured by Johnson & Johnson (J&J), as a fast-acting treatment for patients suffering from treatment-resistant depression. This chemical cousin of ketamine is the first of its kind to be reconsidered as a means of treating patients who have failed to achieve relief…Read more